BioVantra
Client Portal Request Information →
Services / Integrated Urothelial Cytomolecular Testing

Integrated Urothelial
Cytomolecular Testing.

A bladder-focused diagnostic service that brings urine cytology and multi-target FISH together into a single structured interpretation — designed to support bladder cancer detection and surveillance, and to complement cystoscopy, biopsy, imaging, and clinical judgment.

Request Information → Back to Services
Inputs
Cytology · multi-target FISH
Use
Detection & surveillance
Delivery
Structured integrated report
01 · What the service includes

Cytology and FISH,
one integrated read.

Integrated Urothelial Cytomolecular Testing combines morphologic and molecular information from a single voided urine specimen into one structured interpretation. The value is not in two separate test results, but in how cytologic findings and multi-target FISH are reviewed together — with reference to the clinical context — to support bladder cancer detection and surveillance.

A

Urine cytology

Papanicolaou-stained cytology on a voided urine specimen provides morphologic evaluation of urothelial cells. Cytologic review forms the morphologic foundation of the integrated interpretation and supports detection of atypical or suspicious urothelial cells.

B

Multi-target FISH

Fluorescence in situ hybridization evaluates chromosomal abnormalities associated with urothelial carcinoma — aneuploidy of chromosomes 3, 7, and 17, and loss of the 9p21 locus — contributing molecular evidence that cytology alone does not provide.

C

Structured enumeration and interpretation

FISH signals are enumerated on consecutive non-inflammatory cells and classified against defined criteria — multi-chromosome gains, single gains, tetrasomy, and 9p21 loss — then read alongside the cytology to produce a single, consistent interpretation.

D

Clinical correlation for detection and surveillance

The integrated report organizes what is seen cytologically, what is measured molecularly, and what those combined findings are most consistent with — supporting diagnostic workup, recurrence monitoring, and post-treatment follow-up. Localization and management still require correlation with cystoscopy, biopsy, imaging, and clinical context.

02 · Clinical relevance

Where an integrated read
is most useful.

Bladder cancer detection and surveillance depend on information gathered over time, often from non-invasive specimens. Reading cytology and multi-target FISH together — in one structured interpretation — is intended to complement cystoscopy, biopsy, imaging, and clinical judgment rather than to replace them.

  • A

    Detection and surveillance support

    Designed for use in diagnostic workup for suspected urothelial disease and in ongoing surveillance of patients with a history of bladder cancer, including after intravesical therapy.

  • B

    Workup when findings are suspicious or equivocal

    When cytology is atypical or equivocal, the addition of multi-target FISH provides independent molecular evidence that can help characterize the case and inform next steps in the diagnostic pathway.

  • C

    Recurrence monitoring and post-treatment follow-up

    Structured, consistent reporting across visits supports recurrence monitoring and post-treatment follow-up, making findings easier to compare over time as surveillance continues.

  • D

    Complements cystoscopy, biopsy, and imaging

    Positive or suspicious findings can support concern for clinically significant urothelial disease, which may involve the upper or lower genitourinary tract. Further localization and management require correlation with cystoscopy, biopsy, imaging, and the treating clinician’s judgment.

Clinical resources

Download physician-facing reference material related to Integrated Urothelial Cytomolecular Testing.

PDF 01

Integrated Urothelial Cytomolecular Testing Overview

A concise physician-facing overview of the service, report structure, and clinical value.

Open PDF →
PDF 02

Curated Clinical Case & Sample Report

A physician-facing case companion followed by a sample Integrated Urothelial Cytomolecular Report.

Open PDF →
Connect with BioVantra

Talk to us about integrated urothelial cytomolecular testing.

We work with urology practices and clinical teams involved in bladder cancer detection and surveillance. Share a little about your setting and a member of our team will follow up to discuss how this service may fit into your workflow.

Request Information → Contact our team
Existing client? Access diagnostic reports and case history through the Client Portal
Emailcontact@biovantra.com
Phone(352) 861-2296
Fax(352) 671-2737
Address9401 SW Highway 200
STE 502
Ocala, FL 34481-9650